New shot could train body to tolerate peanuts

NCT ID NCT07349212

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new injection called UKK-0018 for people with peanut allergies. The goal is to train the immune system to handle peanut exposure without a severe reaction. The trial involves 40 adults aged 18-55 and will first check safety, then see if it helps increase the amount of peanut protein they can tolerate.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
UKK-0018 (an immunotherapeutic injection)
What this could lead to
If it works, this could lead to a treatment that reduces the risk of severe allergic reactions to peanuts, making accidental exposure less dangerous.
What could go wrong
This is a very early Phase 1/2 trial with only 40 people, so safety and effectiveness are not yet proven. It may not work for everyone, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PEANUT ALLERGY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anaphylaxis food allergy Peanut Hypersensitivity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fiona Stanley Hospital

    NOT_YET_RECRUITING

    Perth, Western Australia, 6150, Australia

  • Flinders Medical Center

    NOT_YET_RECRUITING

    Bedford Park, South Australia, 5042, Australia

  • Pacific Clinical Research Network - Auckland

    RECRUITING

    Takapuna, Auckland, 0622, New Zealand

  • Royal Prince Alfred Hospital

    NOT_YET_RECRUITING

    Camperdown, New South Wales, 2050, Australia

  • The Royal Melbourne Hospital

    RECRUITING

    Fitzroy, Victoria, 3065, Australia

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.